A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors.

Lucy C Sullivan, Nicholas G Walpole, Carine Farenc, Gabriella Pietra, Matthew J W Sum, Craig S Clements, Eleanor J Lee, Travis Beddoe, Michela Falco, Maria Cristina Mingari, Lorenzo Moretta, Stephanie Gras, Jamie Rossjohn, Andrew G Brooks

Journal: The Journal of biological chemistry 2018;292(51):21149-21158

PMID: 28972140

Abstract

αβ T cell receptors (TCRs) interact with peptides bound to the polymorphic major histocompatibility complex class Ia (MHC-Ia) and class II (MHC-II) molecules as well as the essentially monomorphic MHC class Ib (MHC-Ib) molecules. Although there is a large amount of information on how TCRs engage with MHC-Ia and MHC-II, our understanding of TCR/MHC-Ib interactions is very limited. Infection with cytomegalovirus (CMV) can elicit a CD8 T cell response restricted by the human MHC-Ib molecule human leukocyte antigen (HLA)-E and specific for an epitope from UL40 (VMAPRTLIL), which is characterized by biased TRBV14 gene usage. Here we describe an HLA-E-restricted CD8 T cell able to recognize an allotypic variant of the UL40 peptide with a modification at position 8 (P8) of the peptide (VMAPRTLVL) that uses the TRBV9 gene segment. We report the structures of a TRBV9 TCR in complex with the HLA-E molecule presenting the two peptides. Our data revealed that the TRBV9 TCR adopts a different docking mode and molecular footprint atop HLA-E when compared with the TRBV14 TCR-HLA-E ternary complex. Additionally, despite their differing V gene segment usage and different docking mechanisms, mutational analyses showed that the TCRs shared a conserved energetic footprint on the HLA-E molecule, focused around the peptide-binding groove. Hence, we provide new insights into how monomorphic MHC molecules interact with T cells.

© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Address: From the Department of Microbiology and Immunology and Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne 3000, Australia.; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute and.; Department of Experimental Medicine (DiMES) and.; Unità Operativa Complessa Immunologia, Ospedale Policlinico San Martino, 16132 Genoa, Italy.; Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, 00165 Roma, Italy, and.; Center of Excellence for Biomedical Research, University of Genoa, 16132 Genoa, Italy.; Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria 3800, Australia.; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute and [email protected].; Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, Wales, United Kingdom.; From the Department of Microbiology and Immunology and Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne 3000, Australia, [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.